Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Galapagos NV (GLPG : NSDQ)
 
 • Company Description   
Galapagos NV is a biotechnology company. The Company's operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium.

Number of Employees: 1,309

 
 • Price / Volume Information   
Yesterday's Closing Price: $56.34 Daily Weekly Monthly
20 Day Moving Average: 401,300 shares
Shares Outstanding: 65.65 (millions)
Market Capitalization: $3,698.61 (millions)
Beta: 0.49
52 Week High: $81.12
52 Week Low: $46.41
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -12.64% -1.61%
12 Week -14.06% -5.53%
Year To Date 2.19% 26.22%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
GEN DE WITTELAAN L11 A3
-
MECHELEN,C9 2800
BEL
ph: 321-534-2900
fax: 321-534-2901
ir@glpg.com http://www.glpg.com
 
 • General Corporate Information   
Officers
Onno van de Stolpe - Chief Executive Officer
Raj Parekh - Chairman
Bart Filius - President;Chief Operating Officer and Chief Financ
Michele Manto - Chief Commercial Officer
Andre Hoekema - Chief Business Officer

Peer Information
Galapagos NV (CORR.)
Galapagos NV (RSPI)
Galapagos NV (CGXP)
Galapagos NV (BGEN)
Galapagos NV (GTBP)
Galapagos NV (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 36315X101
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 65.65
Most Recent Split Date: (:1)
Beta: 0.49
Market Capitalization: $3,698.61 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.79 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.38 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.25
Price/Cash Flow: -
Price / Sales: 6.41
EPS Growth
vs. Year Ago Period: 8.33%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: 11.43%
vs. Previous Quarter: -6.60%
ROE
03/31/22 - -4.77
12/31/21 - -4.68
09/30/21 - -7.81
ROA
03/31/22 - -2.39
12/31/21 - -2.31
09/30/21 - -3.77
Current Ratio
03/31/22 - 8.44
12/31/21 - 8.58
09/30/21 - 8.72
Quick Ratio
03/31/22 - 8.41
12/31/21 - 8.55
09/30/21 - 8.72
Operating Margin
03/31/22 - -25.63
12/31/21 - -26.44
09/30/21 - -41.92
Net Margin
03/31/22 - -25.71
12/31/21 - -21.76
09/30/21 - -36.28
Pre-Tax Margin
03/31/22 - -24.83
12/31/21 - -25.37
09/30/21 - -41.96
Book Value
03/31/22 - 45.24
12/31/21 - 47.71
09/30/21 - 47.10
Inventory Turnover
03/31/22 - 0.46
12/31/21 - 0.32
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.01
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.69
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©